首页> 美国卫生研究院文献>Cancers >Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
【2h】

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma

机译:可溶性PD-L1是透明细胞肾细胞癌的独立预后因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Renal cell carcinoma (RCC) is a heterogeneous and complex disease with almost no response to chemotherapy. Immune checkpoint inhibitors have achieved great clinical success but no interesting circulating markers of clinical use have developed so far in clear cell renal cell carcinoma (CCRCC). We investigate the diagnostic and prognostic role of plasma PD-1 (sPD-1) and PD-L1 (sPD-L1) proteins for the first time together with the immunohistochemical expression counterpart of these proteins within the tumor front and tumor center in the same sample of patients with renal cancer undergoing surgery. We also investigate these plasma and tissue markers in the population of metastatic patients according to International mRCC Database Consortium (IMDC) prognostic groups and the response to systemic therapy. The independent role of sPD-L1 as a predictor of prognosis and treatment response is demonstrated.
机译:肾细胞癌(RCC)是一种异质和复杂的疾病,几乎没有对化疗的反应。免疫检查点抑制剂已经取得了巨大的临床成功,但在透明细胞肾细胞癌(CCRCC)中,临床使用的有趣循环标记已经开发出来。我们研究了血浆PD-1(SPD-1)和PD-L1(SPD-L1)蛋白的诊断和预后作用首次以及肿瘤前部和肿瘤中心内的这些蛋白质的免疫组化表达对应物。肾癌患者患者进行手术。我们还研究了根据国际MRCC数据库联盟(IMDC)预后群体的转移性患者群体中的这些血浆和组织标记,以及对全身治疗的反应。 SPD-L1作为预后预测和治疗响应的预测的独立作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号